Skip to main content

AGY Therapeutics Turns to Cengent for X-Ray Crystallography

NEW YORK, June 30 - Cengent Therapeutics, formed by the merger in May of Structural Bioinformatics and GeneFormatics, said today that it has signed an agreement with AGY Therapeutics for its X-ray crystallography services.

 

Cengent's technology will be used to produce high-resolution structures of a human target protein and a proprietary inhibitor for AGY's lead optimization efforts in the area of central nervous system disease.

 

The agreement includes up-front and milestone payments, Cengent said. The company did not provide further financial details.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.